共 16 条
- [1] Willemsen M.A., Ijlst L., Steijlen P.M., Rotteveel J.J., de Jong J.G., van Domburg P.H., Mayatepek E., Gabreels F.J., Wanders R.J., Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sjögren-Larsson syndrome, Brain, 124, 7, pp. 1426-1437, (2001)
- [2] Fuijkschot J., Theelen T., Seyger M.M., van der Graaf M., de Groot I.J., Wevers R.A., Wanders R.J., Waterham H.R., Willemsen M.A., Sjogren-Larsson syndrome in clinical practice, J Inherit Metab Dis, 35, 6, pp. 955-962, (2012)
- [3] Rosenbaum P., Paneth N., Leviton A., Goldstein M., Bax M., Damiano D., Dan B., Jacobsson B., A report: the definition and classification of cerebral palsy April 2006, Dev Med Child Neurol Suppl, 109, pp. 8-14, (2007)
- [4] Rizzo W.B., Carney G., Lin Z., The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene, Am J Hum Genet, 65, 6, pp. 1547-1560, (1999)
- [5] Cho K.H., Shim S.H., Kim M., Clinical, biochemical, and genetic aspects of Sjogren-Larsson syndrome, Clin Genet, 93, 4, pp. 721-730, (2018)
- [6] Rizzo W.B., Sjogren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency, Mol Genet Metab, 90, 1, pp. 1-9, (2007)
- [7] Demozay D., Mas J.C., Rocchi S., Van Obberghen E., FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes, Diabetes, 57, 5, pp. 1216-1226, (2008)
- [8] Zarkovic K., 4-Hydroxynonenal and neurodegenerative diseases, Mol Asp Med, 24, 4-5, pp. 293-303, (2003)
- [9] Verhoog J., Fuijkschot J., Willemsen M., Ketelaar M., Rotteveel J., Gorter J.W., Sjogren-Larsson syndrome: motor performance and everyday functioning in 17 patients, Dev Med Child Neurol, 50, 1, pp. 38-43, (2008)
- [10] Kaye E.M., Update on genetic disorders affecting white matter, Pediatr Neurol, 24, 1, pp. 11-24, (2001)